BTAI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -4317.86% compared to BioXcel Therapeutics's net margin of -49.65%. BioXcel Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2348.98%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 43.03%. Given that BioXcel Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe BioXcel Therapeutics is more attractive than NovaBay Pharmaceuticals.

BioXcel Therapeutics has a beta of -0.122, which suggesting that the stock is 112.234% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $168K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. BioXcel Therapeutics's net income of -$7.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 3.45x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -4317.86% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2348.98%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 327.63%. Given that BioXcel Therapeutics has higher upside potential than Nanoviricides, analysts believe BioXcel Therapeutics is more attractive than Nanoviricides.

BioXcel Therapeutics has a beta of -0.122, which suggesting that the stock is 112.234% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $168K, which are larger than Nanoviricides quarterly revenues of --. BioXcel Therapeutics's net income of -$7.3M is lower than Nanoviricides's net income of -$2.2M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 3.45x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -4317.86% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2348.98%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 592.91%. Given that BioXcel Therapeutics has higher upside potential than Oragenics, analysts believe BioXcel Therapeutics is more attractive than Oragenics.

BioXcel Therapeutics has a beta of -0.122, which suggesting that the stock is 112.234% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $168K, which are larger than Oragenics quarterly revenues of --. BioXcel Therapeutics's net income of -$7.3M is lower than Oragenics's net income of -$2.2M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 3.45x versus 1.39x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -4317.86% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2348.98%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1371.52%. Given that BioXcel Therapeutics has higher upside potential than Theriva Biologics, analysts believe BioXcel Therapeutics is more attractive than Theriva Biologics.

BioXcel Therapeutics has a beta of -0.122, which suggesting that the stock is 112.234% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $168K, which are larger than Theriva Biologics quarterly revenues of --. BioXcel Therapeutics's net income of -$7.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 3.45x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.